Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

BRAIN Biotech AG

BRAIN Biotech AG

Actions
  • Price (EUR)2.17
  • Today's Change-0.14 / -6.06%
  • Shares traded1.19k
  • 1 Year change-49.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 27 2024 19:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

  • Revenue in EUR (TTM)56.26m
  • Net income in EUR-8.77m
  • Incorporated2000
  • Employees309.00
More ▼

Institutional shareholders

15.73%Per cent of shares held by top holders
HolderShares% Held
Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 16 Nov 2022698.53k3.20%
Apo Asset Management GmbHas of 30 Sep 2023492.37k2.25%
Wydler Asset Management AGas of 30 Jun 2024458.26k2.10%
Deka Investment GmbHas of 30 Jun 2024417.15k1.91%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2024345.20k1.58%
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbHas of 28 Mar 2024329.39k1.51%
FPM Frankfurt Performance Management AGas of 31 May 2024319.55k1.46%
Deutsche Bank AG (Private Banking Germany)as of 28 Jun 2024222.00k1.02%
UBS Asset Management (Deutschland) GmbHas of 31 Jan 202482.97k0.38%
Generali Investments LLCas of 31 Dec 202371.37k0.33%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.